
Yüksel Ürün/X
Jun 30, 2025, 14:40
Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Dongyin He et al. published in PNAS:
“New player in ARPI-resistant prostate cancer!
HEAL-116, a next-gen 3βHSD1 inhibitor, shows potent tumor suppression, synergy with abiraterone/enzalutamide, and high oral bioavailability.
Structure-guided. Clinically promising.”
Title: Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy
Authors: Dongyin He, Luyao Zhang, Leiye Yu, Yuhang Zhang, Jingjing Chen, Leibo Wang, Haoran Hu, Hongyu Liu, Hong Zheng, Jixin Xia, Jiahui Chen, Chenhui Li, Xin Li, Huiru Tang, Jia Liu, Ruobing Ren, Youhong Hu, Zhenfei Li.
You can read the Full Article in PNAS.
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 30, 2025, 14:40
Jun 30, 2025, 14:18
Jun 30, 2025, 14:06
Jun 30, 2025, 12:08
Jun 30, 2025, 11:38